Lowest Price Guaranteed
Pages
145
Last Updated
July 2026
View Count
10563
1. Market Overview
2. Dashboard: Pipeline and Trial Analysis
3. CTLA-4 Inhibitors: Trial Details
4. PD-1 Inhibitors: Trial Details
5. PDL-1 Inhibitors: Trial Details
6. Novel Immune Checkpoint Inhibitors: Trial Details
7. Molecules in Preclinical Development
8. Inclusion / Exclusion Criteria
9. Drivers and Restraints
10. Market Forecast: Assumptions
11. Market Forecast, 2016-2025
Pipeline and Trial Details
Figure 1 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Highest Phase of Development
Figure 2 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Target
Figure 3 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Phase of Development and Companies
Figure 4 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Type of Molecule
Figure 5 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Key Players
Figure 6 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Trial Phase
Figure 7 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Trial Status
Figure 8 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Sponsor Type
Figure 9 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Tumor Type
Figure 10 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Study Type
Figure 11 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Gender Type
Figure 12 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Molecule Type and Target
Figure 13 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Allocation Type
Figure 14 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Endpoint Classification
Figure 15 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Interventional Model
Figure 16 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Observational Model
Figure 17 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Masking
Figure 18 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Primary Purpose
Figure 19 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by Continent
Figure 20 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by G7 Countries
Figure 21 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by EU5 Countries
Figure 22 Immune Checkpoint Inhibitors in Preclinical Development: Distribution by Companies
Drivers and Restraints
Figure A: CTLA-4 Inhibitors: Drivers and Restraints
Figure B: PD-1 and PDL-1 Inhibitors: Drivers and Restraints
Figure C: Novel Immune Checkpoint Inhibitors: Drivers and Restraints
Market Forecast Analysis
Figure A: Immune Checkpoint Inhibitors Market Forecast, 2016-2025
Pipeline Analysis
Table A Companies Involved in the Development of Preclinical Immune Checkpoint Inhibitorst
Pipeline Details
Table 1 CTLA-4 Inhibitors Clinical Development: Pipeline Details
Table 2 PD-1 Inhibitors Clinical Development: Pipeline Details
Table 3 PDL-1 Inhibitors Clinical Development: Pipeline Details
Table 4 Novel Immune Checkpoint Inhibitors Clinical Development: Pipeline Details
Table 5 Preclinical Development
Market Forecast Analysis
Table A Market Forecast: Assumptions
The following companies and organisations have been mentioned in the report: